Localized pleurodesis chemical delivery

• US 20040225254A1
• Filed: 04/27/2004
• Published: 11/11/2004
• Est. Priority Date: 05/07/2003
• Status: Active Grant

• Current Assignee: Portaero, Inc
• Original Assignee: Portaero, Inc
• Inventors: Tanaka, Don, Russell, Scott M.
• Granted Patent: US 7,811,274 B2
• Time in Patent Office: Days
• US Class Current: 604/58
• CPC Class Codes: A61M 16/10 Preparation of respiratory gases or vapours
• CPC Class Codes: A61M 16/101 using an oxygen concentrator
• CPC Class Codes: A61M 16/107 in the inspiratory path
• CPC Class Codes: A61M 2202/0007 introduced into the body
• CPC Class Codes: A61M 2202/02 Gases
• CPC Class Codes: A61M 2202/0208 Oxygen
• CPC Class Codes: A61M 2202/03 Gases in liquid phase, e.g. cryogenic liquids
• CPC Class Codes: A61M 2210/101 Pleural cavity
• CPC Class Codes: A61M 25/0041 pre-formed, e.g. specially adapted to fit with the anatomy of body channels urethral catheters A61F2/04

Abstract

A long term oxygen therapy system having an oxygen supply directly linked with a patient'"'"'s lung or lungs may be utilized to more efficiently treat hypoxia caused by chronic obstructive pulmonary disease such as emphysema and chronic bronchitis. The system includes an oxygen source, one or more valves and fluid carrying conduits. The fluid carrying conduits link the oxygen source to diseased sites within the patient'"'"'s lungs. A collateral ventilation bypass trap system directly linked with a patient'"'"'s lung or lungs may be utilized to increase the expiratory flow from the diseased lung or lungs, thereby treating another aspect of chronic obstructive pulmonary disease. The system includes a trap, a filter/one-way valve and an air carrying conduit. In order for the system to be effective, an air-tight seal between the parietal and visceral pleurae is required. Chemical pleurodesis is utilized for creating the seal.

Claims

1. A device for the local delivery of a pleurodesis agent, the device comprising:

a catheter having one or more fluid carrying conduits; and

a distal tip attached to and in fluid communication with the catheter, the distal tip being sized and configured to deliver a pleurodesis agent to a predetermined area in a pleural space of a patient.

2. The device for the local delivery of a pleurodesis agent according to claim 1, wherein the distal tip comprises a substantially circular configuration.

3. The device for the local delivery of a pleurodesis agent according to claim 2, wherein the distal tip comprises a plurality of openings in fluid communication with the one or more fluid carrying conduits and oriented such that the pleurodesis agent, is released towards a center point of the substantially circular configuration of the distal tip.

4. The device for the local delivery of a pleurodesis agent according to claim 1, wherein the agent comprises talc.

5. The device for the local delivery of a pleurodesis agent according to claim 1, wherein the agent comprises tetracycline.

6. The device for the local delivery of a pleurodesis agent according to claim 1, wherein the agent comprises doxycycline.

7. The device for the local delivery of a pleurodesis agent according to claim 1, wherein the agent comprises bleomycin.

8. The device for the local delivery of a pleurodesis agent according to claim 1, wherein the agent comprises minocycline.

9. The device for the local delivery of a pleurodesis agent according to claim 1, wherein the agent comprises a radiopaque material.

10. The device for the local delivery of a pleurodesis agent according to claim 1, wherein the agent comprises a material to increase its viscosity.

11. A device for the local delivery of a pleurodesis agent, the device comprising:

an implantable medical device for implantation at a predetermined site in a pleural space of a patient; and

a pleurodesis agent affixed to the implantable medical device.

12. The device for the local delivery of a pleurodesis agent according to claim 11, wherein the implantable medical device comprises a substantially circular disk.

13. The device for the local delivery of a pleurodesis agent according to claim 11, wherein the implantable medical device comprises a biodegradable material.

14. The device for the local delivery of a pleurodesis agent according to claim 11, wherein the implantable medical device comprises a non-biodegradable material.

15. The device for the local delivery of a pleurodesis agent according to claim 11, wherein the implantable medical device comprises a polymeric material.

16. The device for the local delivery of a pleurodesis agent according to claim 11, wherein the implantable medical device comprises a metallic material.

17. The device for the local delivery of a pleurodesis agent according to claim 11, wherein the implantable medical device comprises a radiopaque marker.

18. The device for the local delivery of a pleurodesis agent according to claim 11, wherein the implantable medical device comprises a plurality of openings for storing and releasing the pleurodesis agent.

19. The device for the local delivery of a pleurodesis agent according to claim 11, further comprising a biocompatible coating affixed to the implantable medical device.

20. The device for the local delivery of a pleurodesis agent according to claim 19, wherein the pleurodesis agent is incorporated into the biocompatible coating.

21. The device for the local delivery of a pleurodesis agent according to claim 19, wherein the pleurodesis agent is sandwiched between the biocompatible coating and the implantable medical device.

22. The device for the local delivery of a pleurodesis agent according to claim 11, wherein the agent comprises talc.

23. The device for the local delivery of a pleurodesis agent according to claim 11, wherein the agent comprises tetracycline.

24. The device for the local delivery of a pleurodesis agent according to claim 11, wherein the agent comprises doxycycline.

25. The device for the local delivery of a pleurodesis agent according to claim 11, wherein the agent comprises bleomycin.

26. The device for the local delivery of a pleurodesis agent according to claim 11, wherein the agent comprises minocycline.